/
We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries.
The business is unprofitable at the operating level (-3.49% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 20.2%, still solid. Free cash flow declined 305% despite revenue growth, conversion is weakening.
Free cash flow declined 305% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$3M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$238M
▲ +20.2% YoY
Net Income (TTM)
-$31M
▼ -57.6% YoY
Op. Margin
-3.79%
▼ -1.7pp YoY
ROIC
-3.43%
▼ -1.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$9M
▼ -304.5% YoY
Op. Cash Flow (TTM)
$16M
▼ -82.1% YoY
Net Debt
-$81M
Net Cash Position
Cash & Equiv.
$102M
5Y CAGR: +14.9%
Continue Research